<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="respiratory tract illness in infants and young children worldwide. The" exact="World Health Organization" post="recognizes the need to develop and implement prevention strategies"/>
 <result pre="no RSV vaccine is currently available to prevent RSV, the" exact="World Health Organization" post="(WHO) estimates that an RSV vaccine will be in"/>
 <result pre="the Pregnancy Influenza Vaccine Effectiveness Network (PREVENT) of the US" exact="Centers for Disease Control and Prevention" post="and sites in four countries evaluated the impact of"/>
 <result pre="monoclonal antibody specific for the F-protein of RSV, Palivizumab (Synagis;" exact="MedImmune" post="and AstraZeneca, Cambridge, UK), was evaluated and approved in"/>
 <result pre="UK), was evaluated and approved in 1998 by the US" exact="Food and Drug Administration" post="(FDA) for use by intramuscular injection in high-risk children."/>
 <result pre="York, NY), Pre-F with and without adjuvant. Source: Adapted from" exact="PATH" post="https://www.path.org/resources/rsv-vaccine-and-mab-snapshot/. Maternal immunization for the prevention of RSV in"/>
 <result pre="consultation on respiratory syncytial virus vaccine development report from a" exact="World Health Organization" post="meeting held on 23-24 March 2015Vaccine34220161901972610092626100926 2HallC.B.WeinbergG.A.IwaneM.K.BlumkinA.K.EdwardsK.M.StaatM.A.The burden of"/>
</results>
